AtriCure, Inc. 8K

AtriCure announced strong second quarter 2026 results with double-digit revenue growth, a return to profitability, and raised visibility via full-year 2026 financial guidance.

AtriCure, Inc. reported its second quarter 2026 financial results, highlighting worldwide revenue of $153.6 million (up 12.8% year over year), a swing to profitability with net income of $9.0 million and adjusted EBITDA of $27.3 million, stronger gross margins driven by favorable mix and manufacturing efficiencies, and positive cash generation of $21.6 million, while also issuing full-year 2026 guidance for revenue of $602–$610 million, adjusted EBITDA of $85–$89 million, net income per share of $0.05–$0.13, and adjusted EPS of $0.24–$0.32, supported by growth in pain management, open ablation, and appendage management product lines and ongoing clinical trials such as BoxX-NoAF and LeAAPS.

Filing Facts

CIK

1323885

Ticker

-

Form

8K

Source Type

sec

Accession

0001323885-26-000032

Alert Tier

7